Compare Petróleo Brasileiro SA (PBR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Revvity Inc — how do they compare? Petróleo Brasileiro SA trades at $25.43 (market cap $151.94B), while Revvity Inc trades at $154.66 (market cap $16.98B). The key difference: Petróleo Brasileiro SA is far larger — about 8.9× Revvity Inc's market cap, and Petróleo Brasileiro SA pays the higher dividend (6.79%). Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and Revvity Inc for 12 Days on average.
| PBR | RVTY | |
|---|---|---|
Market Cap | $151.94B | $16.98B |
Volume | 30,240,092 | 1,456,900 |
Sector | Energy | Health |
52-Week High | $24.69 | $157.36 |
52-Week Low | $11.54 | $82.26 |
Typical Hold Time | 25 Days | 12 Days |
Enterprise Value | $212.36B | $19.30B |
Dividend Yield | 6.79% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) is trading at $25.16, up 4.88% with strong bullish momentum. The stock shows robust fundamentals with a P/E of 6.24, net margin of 24.52%, and positive earnings surprises in recent quarters. Recent news highlights new oil discoveries and production growth initiatives, while technical indicators show overbought conditions with RSI above 80.
PBR offers attractive valuation metrics and strong profitability, but faces risks from political interference and commodity price volatility. Analyst consensus leans bullish with 50% buy ratings, though the current price exceeds the $22.33 consensus target. The company's expansion projects and LNG deals provide long-term growth catalysts.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
